In the recent article, “Antisense Oligonucleotide Therapy for Calmodulinopathy,” we provided the first proof-of-concept in ...

His autopsy report, published in the New England Journal of Medicine, noted that DeMar’s left main coronary artery contained ...

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention ...

Elevated plasma levels of Lp(a) [lipoprotein(a)] are a causal risk factor for coronary heart disease and stroke in European individuals, but the causal relevance of Lp(a) for different stroke types ...

Background: There is sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), where lesions beyond pulmonary vein isolation (PVI) ...

Background: Intramural site of origin is a major cause of ablation failure of ventricular arrhythmias and the optimal strategy is unclear. This study investigated the efficacy of a stepwise ablation ...

The adult vascular system is a developmental mosaic. This is particularly true for vascular SMCs that comprise the medial layer of blood vessels throughout the body. 1 SMCs are specialized ...

Background: The PRAETORIAN trial investigated the efficacy and safety of the subcutaneous implantable cardioverter-defibrillator (S-ICD) compared with transvenous ICD (TV-ICD) and showed ...

New Cornerstone Investigator Institute, State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of ...

In this issue of Stroke, Dittrich et al report the timely results of a retrospective analysis comparing mechanical thrombectomy with usual care in 190 patients with anterior circulation large vessel ...

Although CTPA has largely solved the diagnostic question, “Does the patient have PE?” new questions have arisen. These include: Do patients warrant concurrent CTPA plus imaging of the pelvis and lower ...

Figure 1. Examples of new therapeutic approaches targeting immune responses to limit cardiovascular disease burden. 1, Low-dose IL (interleukin)-2 to induce the expansion of natural regulatory T cells ...